论文部分内容阅读
目的评价中药艾迪注射液联合西药卡铂注射液治疗癌性胸水的临床疗效。方法 60例原发性肺癌合并癌性胸水的患者分为观察组和对照组,两组均采用胸腔内置管引流胸水后,胸腔内注射卡铂注射液,治疗组加用艾迪注射液静脉滴注,比较两组的有效率,并评价两组的临床疗效和不良反应。结果治疗4周后,治疗组总有效率为83.33%,对照组为66.67%,P<0.05;治疗组不良反应4例,不良反应率13.33%,对照组不良反应9例,不良反应率30.00%(P<0.05)。结论中药艾迪注射液静脉滴注联合卡铂注射液胸腔内给药能有效控制原发性肺癌患者胸水的增长,降低不良反应发生。
Objective To evaluate the clinical efficacy of Aidi injection combined with carboplatin injection in the treatment of cancerous pleural effusion. Methods Sixty patients with primary lung cancer complicated with cancerous pleural effusion were divided into observation group and control group. Both groups were treated with intrathoracic drainage of pleural effusion, intrathoracic injection of carboplatin injection, and treatment group with Aidi injection Note, comparing the two groups of effective rate, and evaluate the clinical efficacy and adverse reactions in both groups. Results After 4 weeks of treatment, the total effective rate was 83.33% in the treatment group and 66.67% in the control group, P <0.05; 4 cases of adverse reactions in the treatment group, the adverse reaction rate was 13.33%, 9 cases of adverse reactions in the control group, the adverse reaction rate was 30.00% (P <0.05). Conclusion Intravenous injection of Aidi Injection and carboplatin can effectively control the growth of pleural effusion in patients with primary lung cancer and reduce the incidence of adverse reactions.